// App-Quantinova.ai

OP0019 (2022) : BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY

Researchers

Presenter

  • D. Van der Heijde

Principal Investigators

  • X. Baraliakos

  • M. Dougados

  • M. Brown

  • D. Poddubnyy

  • F. Van den Bosch

  • N. Haroon

  • H. Xu

  • T. Tomita

  • L. S. Gensler

  • M. Oortgiesen

  • C. Fleurinck

  • T. Vaux

  • A. Marten

  • A. Deodhar

Medical Centers

  • Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands

  • Ruhr-University Bochum, Rheumazentrum Ruhrgebiet, Bochum, Germany

  • Université de Paris, Department of Rheumatology – Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris, France

  • Genomics England, London, United Kingdom

  • Charite - University Medicine Berlin, Department of Medicine (Gastroenterology, Infectious Diseases, Rheumatology), Berlin, Germany

  • Ghent University and VIB Centre for Inflammation Research, Department of Internal Medicine and Paediatrics, Ghent, Belgium

  • University of Toronto, University Health Network, Toronto, Ontario, Canada

  • Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Department of Rheumatology and Immunology, Shanghai, China

  • Osaka University Graduate School of Medicine, Department of Orthopaedic Biomaterial Science, Osaka, Japan

  • UCB Pharma, Raleigh, United States of America

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Monheim, Germany

  • Oregon Health and Science University, Rheumatology Clinica Division of Arthritis and Rheumatic Diseases, Portland, United States of America

Locations

  • Netherlands

  • Germany

  • France

  • United Kingdom

  • Belgium

  • Canada

  • China

  • Japan

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03928743

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved